GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Accelerated Pharma Inc (NAS:ACCP) » Definitions » Interest Coverage

Accelerated Pharma (Accelerated Pharma) Interest Coverage : 0 (At Loss) (As of Mar. 2017)


View and export this data going back to 2016. Start your Free Trial

What is Accelerated Pharma Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Accelerated Pharma's Operating Income for the three months ended in Mar. 2017 was $-0.41 Mil. Accelerated Pharma's Interest Expense for the three months ended in Mar. 2017 was $-0.28 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Accelerated Pharma's Interest Coverage or its related term are showing as below:


ACCP's Interest Coverage is not ranked *
in the Drug Manufacturers industry.
Industry Median: 12.275
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Accelerated Pharma Interest Coverage Historical Data

The historical data trend for Accelerated Pharma's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Accelerated Pharma Interest Coverage Chart

Accelerated Pharma Annual Data
Trend Dec14 Dec15 Dec16
Interest Coverage
N/A - -

Accelerated Pharma Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Interest Coverage Get a 7-Day Free Trial - - - - -

Competitive Comparison of Accelerated Pharma's Interest Coverage

For the Drug Manufacturers - Specialty & Generic subindustry, Accelerated Pharma's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Accelerated Pharma's Interest Coverage Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Accelerated Pharma's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Accelerated Pharma's Interest Coverage falls into.



Accelerated Pharma Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Accelerated Pharma's Interest Coverage for the fiscal year that ended in Dec. 2016 is calculated as

Here, for the fiscal year that ended in Dec. 2016, Accelerated Pharma's Interest Expense was $-0.83 Mil. Its Operating Income was $-3.20 Mil. And its Long-Term Debt & Capital Lease Obligation was $1.21 Mil.

Accelerated Pharma did not have earnings to cover the interest expense.

Accelerated Pharma's Interest Coverage for the quarter that ended in Mar. 2017 is calculated as

Here, for the three months ended in Mar. 2017, Accelerated Pharma's Interest Expense was $-0.28 Mil. Its Operating Income was $-0.41 Mil. And its Long-Term Debt & Capital Lease Obligation was $1.23 Mil.

Accelerated Pharma did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Accelerated Pharma  (NAS:ACCP) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Accelerated Pharma Interest Coverage Related Terms

Thank you for viewing the detailed overview of Accelerated Pharma's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Accelerated Pharma (Accelerated Pharma) Business Description

Traded in Other Exchanges
N/A
Address
Website
Accelerated Pharma Inc, is a Delaware corporation organized on May 12, 2014. It is a biopharmaceutical company focused on utilizing its genomic technology to enhance the development and commercialization of pharmaceutical products. Its lead product candidate is Picoplatin, a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications.

Accelerated Pharma (Accelerated Pharma) Headlines

No Headlines